NYSE:EHC

Encompass Health Stock Forecast, Price & News

$75.92
-0.49 (-0.64 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$75.01
$76.66
50-Day Range
$75.92
$80.81
52-Week Range
$60.44
$89.68
Volume1.36 million shs
Average Volume600,386 shs
Market Capitalization$7.55 billion
P/E Ratio19.77
Dividend Yield1.47%
Beta1.1
30 days | 90 days | 365 days | Advanced Chart
Receive EHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Encompass Health and its competitors with MarketBeat's FREE daily newsletter.


Encompass Health logo

About Encompass Health

Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provides rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations. The Home Health and Hospice segment provides Medicare-certified home nursing, specialized home care and in-home services. The company was founded by Richard M. Scrushy on February 22, 1984 and is headquartered in Birmingham, AL.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.92 out of 5 stars

Medical Sector

11th out of 1,350 stocks

Hospitals Industry

2nd out of 8 stocks

Analyst Opinion: 3.6Community Rank: 5.0Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Encompass Health (NYSE:EHC) Frequently Asked Questions

Is Encompass Health a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Encompass Health in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Encompass Health stock.
View analyst ratings for Encompass Health
or view top-rated stocks.

What stocks does MarketBeat like better than Encompass Health?

Wall Street analysts have given Encompass Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Encompass Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Encompass Health's next earnings date?

Encompass Health is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Encompass Health
.

How were Encompass Health's earnings last quarter?

Encompass Health Co. (NYSE:EHC) posted its quarterly earnings data on Monday, July, 26th. The company reported $1.17 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.98 by $0.19. The business had revenue of $1.29 billion for the quarter, compared to analysts' expectations of $1.28 billion. Encompass Health had a trailing twelve-month return on equity of 19.49% and a net margin of 7.83%. The firm's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.34 earnings per share.
View Encompass Health's earnings history
.

How has Encompass Health's stock been impacted by COVID-19 (Coronavirus)?

Encompass Health's stock was trading at $63.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EHC shares have increased by 18.9% and is now trading at $75.92.
View which stocks have been most impacted by COVID-19
.

How often does Encompass Health pay dividends? What is the dividend yield for Encompass Health?

Encompass Health announced a quarterly dividend on Tuesday, July 20th. Stockholders of record on Friday, October 1st will be paid a dividend of $0.28 per share on Friday, October 15th. This represents a $1.12 dividend on an annualized basis and a yield of 1.48%. The ex-dividend date of this dividend is Thursday, September 30th.
View Encompass Health's dividend history
.

Is Encompass Health a good dividend stock?

Encompass Health pays an annual dividend of $1.12 per share and currently has a dividend yield of 1.47%. The dividend payout ratio of Encompass Health is 38.75%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Encompass Health will have a dividend payout ratio of 24.14% next year. This indicates that Encompass Health will be able to sustain or increase its dividend.
View Encompass Health's dividend history.

What guidance has Encompass Health issued on next quarter's earnings?

Encompass Health issued an update on its FY 2021 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share (EPS) guidance of $4.320-$4.470 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.110. The company issued revenue guidance of $5.10 billion-$5.25 billion, compared to the consensus revenue estimate of $5.14 billion.

What price target have analysts set for EHC?

7 analysts have issued 12 month price targets for Encompass Health's stock. Their forecasts range from $94.00 to $110.00. On average, they expect Encompass Health's share price to reach $102.14 in the next twelve months. This suggests a possible upside of 34.5% from the stock's current price.
View analysts' price targets for Encompass Health
or view top-rated stocks among Wall Street analysts.

Who are Encompass Health's key executives?

Encompass Health's management team includes the following people:
  • Mark J. Tarr, President, Chief Executive Officer & Director
  • Douglas E. Coltharp, Chief Financial Officer & Executive Vice President
  • Elissa Joy Charbonneau, Chief Medical Officer
  • John Patrick Darby, Secretary, Executive VP & General Counsel
  • Andrew L. Price, Chief Accounting Officer & Senior Vice President

What is Mark Tarr's approval rating as Encompass Health's CEO?

231 employees have rated Encompass Health CEO Mark Tarr on Glassdoor.com. Mark Tarr has an approval rating of 79% among Encompass Health's employees.

Who are some of Encompass Health's key competitors?

What other stocks do shareholders of Encompass Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Encompass Health investors own include salesforce.com (CRM), Johnson & Johnson (JNJ), Alibaba Group (BABA), CVS Health (CVS), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Pfizer (PFE), Verizon Communications (VZ) and Advanced Micro Devices (AMD).

What is Encompass Health's stock symbol?

Encompass Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EHC."

Who are Encompass Health's major shareholders?

Encompass Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.74%), Vanguard Group Inc. (9.36%), William Blair Investment Management LLC (3.98%), State Street Corp (2.60%), American Century Companies Inc. (1.78%) and Victory Capital Management Inc. (1.70%). Company insiders that own Encompass Health stock include Andrew L Price, Andrew L Price, Donald L Correll, Donald L Correll, Elissa Joy Charbonneau, Elissa Joy Charbonneau, Mark J Tarr and Mark J Tarr.
View institutional ownership trends for Encompass Health
.

Which major investors are selling Encompass Health stock?

EHC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, William Blair Investment Management LLC, American Century Companies Inc., Principal Financial Group Inc., Victory Capital Management Inc., BlackRock Inc., Epoch Investment Partners Inc., and Envestnet Asset Management Inc.. Company insiders that have sold Encompass Health company stock in the last year include Andrew L Price, and Elissa Joy Charbonneau.
View insider buying and selling activity for Encompass Health
or view top insider-selling stocks.

Which major investors are buying Encompass Health stock?

EHC stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Point72 Asset Management L.P., Man Group plc, Great Lakes Advisors LLC, State Street Corp, Los Angeles Capital Management LLC, Magnetar Financial LLC, and Qube Research & Technologies Ltd.
View insider buying and selling activity for Encompass Health
or or view top insider-buying stocks.

How do I buy shares of Encompass Health?

Shares of EHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Encompass Health's stock price today?

One share of EHC stock can currently be purchased for approximately $75.92.

How much money does Encompass Health make?

Encompass Health has a market capitalization of $7.55 billion and generates $4.64 billion in revenue each year. The company earns $284.20 million in net income (profit) each year or $2.89 on an earnings per share basis.

How many employees does Encompass Health have?

Encompass Health employs 43,000 workers across the globe.

When was Encompass Health founded?

Encompass Health was founded in 1984.

What is Encompass Health's official website?

The official website for Encompass Health is www.healthsouth.com.

Where are Encompass Health's headquarters?

How can I contact Encompass Health?

Encompass Health's mailing address is 3660 Grandview Pkwy Ste 200, BIRMINGHAM, AL 35243-3332, United States. The company can be reached via phone at (205) 967-7116 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.